Clinical Quiz: Lipid Management Principles from 2019 ESC/EAS Guidelines on Dyslipidemia


Check out the first in our series of quizzes testing your knowledge the ESC/EAS 2019 guidelines on dyslipidemia. this quiz focuses on basic lipid management principles!

The management of dyslipidemia has undergone a transformation since the turn of the century, driven by advances in understanding pathophysiology as well as developments in pharmacological therapies.

For decades, statins were not only the centerpiece, but often the only option for many patients who struggled with lipid disorders. While their role as a mainstay in therapy has persisted through time as a result of their affordability, efficacy, and established safety profile, the advent of new therapies has redefined what is considerable an optimal approach to management of dyslipidemia for many. With such a rapid rate of advancements, the release of updated guidance has become paramount.

In this clinical quiz, we test your knowledge of basic lipid management principles from the 2019 European Society of Cardiology/European Atherosclerosis Society Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk.

Of note, this is the first in a series of 4 quizzes based on these guidelines. Check back for more quizzes on risk assessment, pharmacotherapy, and nonpharmacologic interventions in the coming weeks!

Quizzes in this series:

Quiz 1: Lipid Management Principles from 2019 ESC/EAS Guidelines on Dyslipidemia

Quiz 2: Risk Assessment and Stratification from 2019 ESC/EAS Guidelines on Dyslipidemia

Quiz 3: Pharmacotherapy Recommendations from ESC/EAS 2019 Dyslipidemia Guidelines

Quiz 4: Lifestyle and Nonpharmacological Interventions from ESC/EAS 2019 Dyslipidemia Guidelines

According to the 2019 ESC/EAS guidelines, what is the target LDL-C level for patients with documented atherosclerotic cardiovascular disease (ASCVD) who are considered very high risk?


Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk [published correction appears in Eur Heart J. 2020 Nov 21;41(44):4255. doi: 10.1093/eurheartj/ehz826]. Eur Heart J. 2020;41(1):111-188. doi:10.1093/eurheartj/ehz455

Related Videos
Brendon Neuen, MBBS, PhD | Credit:
4 KOLs are featured in this series
4 KOLs are featured in this series
M. Safwan Badr, MD: Novel Treatments for Central Sleep Apnea in Last 10 Years
Video 4 - Featuring 3 KOLs in, "Implementing Treat to Target in the Long-term in Inflammatory Bowel Disease "
Video 3 - Featuring 3 KOLs in, "How important is transmural healing as a treatment target in UC and CD?   Where does intestinal ultrasound fit in CD management?  "
How Elite Athletes Can Optimize Sleep for Peak Performance, with Jesse D. Cook, PhD
Boadie Dunlop, MD, Weighs in on FDA Advisory Vote on Lykos’ MDMA
© 2024 MJH Life Sciences

All rights reserved.